Progesterone Receptor (Ser190) Antibody

There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005) . The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms) . In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000; Lin et al., 2003) . Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser-190 and Ser-294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor.

NR3C3 antibody, Nuclear receptor subfamily 3 group C member 3 antibody, PGR antibody, PR antibody, PRA antibody, PRB antibody, PRGR_HUMAN antibody, Progesterone receptor antibody, Progestin receptor form A antibody, Progestin receptor form B antibody

Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser190 of human progesterone receptor, conjugated to keyhole limpet hemocyanin (KLH) .

Specific for endogenous levels of the ~90 kDa PR-A isoform and the ~120 kDa PR-B isoform phosphorylated at Ser190. Immunolabeling is blocked by preadsorption with the phosphopeptide used as antigen, but not by the corresponding non-phosphopeptide.